Stay updated with breaking news from Interim Data From. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life when compared to baseline Clinically important improvements seen for all...
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient... | June 10, 2023
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present seven abstracts from across its neuroscience portfolio at...
Seventeen abstracts debut new data across narcolepsy and idiopathic hypersomnia DUBLIN, June 1, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 17 new abstracts from across its...